Asset Details
Do you wish to reserve the book?
A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures
Do you wish to request the book?
A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures
2026
Overview
Allogeneic virus-specific T cell (VST) therapies offer distinct advantages, including scalability, rapid deployment, and manufacturing consistency, and have demonstrated efficacy in multiple clinical trials. However, identifying VST products with high therapeutic potential remains a major hurdle. Here, we present a multidimensional analytical platform that integrates in vitro and in vivo anti-viral reactivity, T cell receptor (TCR) repertoire analysis, gene expression profiling, immunophenotyping, and functional validation in a humanized mouse model. Epstein-Barr virus (EBV)-specific T cells expanded from HLA-diverse healthy donors consistently enriched for TCRs targeting EBV-encoded antigens. Transcriptomic and high-dimensional flow cytometric analyses revealed a distinct effector-associated signature. Importantly, this integrative approach uncovered correlative biomarkers of T cell potency and effector function, validated in an in vivo model of EBV-driven B cell lymphoma. These findings establish a scalable framework for the characterization of allogeneic T cell products and may inform the development of predictive metrics for in vivo efficacy.
Allogeneic T cell therapies could be used in therapeutic applications because of their potential for ‘off-the-shelf’ access and standardised production. Here the authors have developed a multidimensional workflow profiling platform for EBV-specific T cell therapy and show that correlative biomarkers of T cell potency and effector function are associated with therapeutic effectiveness in xenogeneic mouse EBV-LCL models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/31
/ 38
/ 38/39
/ Animals
/ Antigens
/ Epstein-Barr Virus Infections - immunology
/ Epstein-Barr Virus Infections - therapy
/ Herpesvirus 4, Human - immunology
/ Humanities and Social Sciences
/ Humans
/ Immunotherapy, Adoptive - methods
/ Lymphoma
/ Lymphoma, B-Cell - immunology
/ Mice
/ Peptides
/ Receptors, Antigen, T-Cell - genetics
/ Receptors, Antigen, T-Cell - immunology
/ Receptors, Antigen, T-Cell - metabolism
/ Science
/ T-Lymphocytes - transplantation
/ Viruses
/ Workflow
